Research programme: macrocyclic compounds - Cyclenium Pharma

Drug Profile

Research programme: macrocyclic compounds - Cyclenium Pharma

Alternative Names: Cancer therapeutics - Cyclenium/Southern Research Institute; Cancer therapeutics - Cyclenium/University of Montreal; Gastrointestinal and metabolic disorders therapeutics - Cyclenium; Immunological disorder therapeutics - Cyclenium/University of Montreal; Infectious diseases therapeutics - Cyclenium/Fundación MEDINA; Infectious diseases therapeutics - Cyclenium/Southern Research Institute; Inflammation and pain therapeutics - Cyclenium; Neurological disorder therapeutics - Cyclenium/Southern Research Institute

Latest Information Update: 10 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cyclenium Pharma
  • Developer Cyclenium Pharma; Fundacion MEDINA; SickKids; Southern Research Institute; University of Montreal
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal disorders; Metabolic disorders

Highest Development Phases

  • Research Cancer; Cardiovascular disorders; Immunological disorders; Infections; Neurological disorders

Most Recent Events

  • 07 Mar 2017 Early research in Cardiovascular disorders in USA (unspecified route)
  • 07 Mar 2017 Cyclenium Pharma and SickKids agree to co-develop macrocyclic compounds for indications immunological disorders, cardiovascular disorders and cancer
  • 11 Jun 2015 Cyclenium Pharma and McGill University agree to co-develop macrocyclic compounds in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top